Compare Merck & Co., Inc. (MRK) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Shell PLC — how do they compare? Merck & Co., Inc. trades at $133.42 (market cap $321.77B), while Shell PLC trades at $90.31 (market cap $250.44B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Shell PLC pays the higher dividend (3.45%). Which is the better fit depends on your goals.
| MRK | SHEL | |
|---|---|---|
Market Cap | $321.77B | $250.44B |
Sector | Health | Energy |
52-Week High | $131.84 | $94.15 |
52-Week Low | $77.60 | $70.31 |
Enterprise Value | $368.53B | $292.14B |
Dividend Yield | 2.61% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Shell (SHEL) trades at $90.15, up 0.22% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.60. Recent Q2 2026 earnings beat estimates with EPS of $3.52 versus $3.23 expected, driven by higher oil prices and strong operational performance. The company maintains solid profitability with a net income margin of 8.76% and ROE of 14.35%, while cash flow from operations reached $42.86B in 2025.
Outlook is positive due to undervaluation (P/E of 10.01), rising oil prices, and strategic asset sales, but risks include commodity volatility and geopolitical tensions affecting energy markets. With 69% of analysts rating it Buy and institutional support, SHEL offers growth potential, though investors should monitor debt levels and global energy demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
